Back to Search
Start Over
2- 18 F-Fluoroethanol Is a PET Reporter of Solid Tumor Perfusion.
- Source :
-
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2017 May; Vol. 58 (5), pp. 815-820. Date of Electronic Publication: 2017 Jan 26. - Publication Year :
- 2017
-
Abstract
- Solid tumor perfusion is a proven variable of interest for predicting cancer aggression and response to therapy. Current methods for noninvasively imaging tumor perfusion with PET are limited by restricted accessibility and short half-lives of perfusion radiotracers. This study presents 2- <superscript>18</superscript> F-fluoroethanol (2- <superscript>18</superscript> F-FEtOH) as a perfusion reporter that can distinguish between tumors of varying perfusion levels and can be applied to screening drugs that modify tumor perfusion. Methods: Uptake of 2- <superscript>18</superscript> F-FEtOH in 4T1 and 67NR murine mammary carcinoma tumors grown in mice was measured using ex vivo radiography as well as static and dynamic PET imaging. 2- <superscript>18</superscript> F-FEtOH uptake was directly compared with the <superscript>14</superscript> C-iodoantipyrine perfusion reporter, and the perfusion-modifying drugs nicotinamide, pentoxifylline, and hydralazine were used to manipulate tumor perfusion before 2- <superscript>18</superscript> F-FEtOH quantification. Results: Uptake of 2- <superscript>18</superscript> F-FEtOH in 4T1 and 67NR tumors was consistent with known perfusion differences within and between these tumors. 2- <superscript>18</superscript> F-FEtOH uptake corresponded well with <superscript>14</superscript> C-iodoantipyrine and reflected the tumor perfusion-modifying effects of each drug. Conclusion: 2- <superscript>18</superscript> F-FEtOH is a novel <superscript>18</superscript> F-based radiotracer for investigating tumor perfusion with PET imaging. Quantification of 2- <superscript>18</superscript> F-FEtOH uptake can be used to distinguish between tumors of varying perfusion and to screen the efficacy of blood flow-modifying drugs for use as adjuvants to existing cancer therapies.<br /> (© 2017 by the Society of Nuclear Medicine and Molecular Imaging.)
- Subjects :
- Animals
Cell Line, Tumor
Diagnosis, Differential
Ethanol pharmacokinetics
Female
Mammary Neoplasms, Experimental complications
Metabolic Clearance Rate
Mice
Mice, Inbred BALB C
Neoplasms
Neovascularization, Pathologic etiology
Radiopharmaceuticals pharmacokinetics
Reproducibility of Results
Sensitivity and Specificity
Tissue Distribution
Ethanol analogs & derivatives
Mammary Neoplasms, Experimental diagnostic imaging
Mammary Neoplasms, Experimental metabolism
Neovascularization, Pathologic diagnostic imaging
Neovascularization, Pathologic metabolism
Positron-Emission Tomography methods
Subjects
Details
- Language :
- English
- ISSN :
- 1535-5667
- Volume :
- 58
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 28126891
- Full Text :
- https://doi.org/10.2967/jnumed.116.183624